Business Context and Reporting Period
This Form 8-K filing by Galectin Therapeutics Inc. (Nasdaq: GALT) reports a corporate governance event. The report date is January 10, 2026, covering the resignation of a Board member.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the departure of Marc Rubin from the Board of Directors, effective January 10, 2026. The Company explicitly states that the resignation is not the result of any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are disclosed in this document other than the standard disclosure of the director's departure.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Mr. Rubin's resignation.
- Confirm whether a replacement director has been nominated or appointed.
- Review recent 10-K or 10-Q filings for the Company's actual financial position, as this 8-K contains no financial data.